Meanwhile, this on-target/off-tumor toxicity of CD147-CAR-NK or CD147-CAR-T cell therapy may be manageable by introducing suicide genes76, using messenger RNA transfection77, a split, universal, and programmable CAR system78, intratumoral injections of CAR-modified cells79, or a synNotch CAR design80–82. The gene discussed is BSG; the disease is neoplasm.